All posts by CAC2

What is a Pediatric Study Plan?

Our May CAC2 All-Member webinar focused on how pediatric cancer study plans are developed.  CAC2 Member Kelli Wright (CureSearch) introduced Dr. Brenda Weigel from University of Minnesota’s Masonic Cancer Center and Dr. Samuel Blackman of Day One Biopharmaceuticals as they addressed:   What is a Pediatric Study Plan (PSP)? How [...]

Day One Biopharmaceuticals

Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.  Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of […]

Joint Webinar Presentation: The Pandemic’s Impact on the Pediatric Cancer Research Landscape

Solving Kids’ Cancer and Max Cure Foundation offered a joint webinar: The Pandemic’s Impact on the Pediatric Cancer Research Landscape Timothy P. Cripe, Chief of Hematology and Oncology at Nationwide Children’s Hospital moderated the session that featured an all-star line-up: Peter Adamson, MD – former Chair, Children’s Oncology Group (COG) […]